Interpace Biosciences Inc.

08/21/2026 | Press release | Distributed by Public on 08/21/2026 04:01

Proxy Results (Form 8-K)

Item 5.07. Submission of Matters to a Vote of Security Holders.

On August 20, 2026, the Company held its 2026 annual meeting of stockholders (the "2026 Annual Meeting"). The following proposals were voted on and approved by the Company's stockholders at the 2026 Annual Meeting with the stockholders having voted as set forth below.

I. Proposal to approve Amended and Restated Certificate of Incorporation.
For Against Abstain Broker Non-Vote
24,981,181 246,552 3,625 1,347,136
II. Proposal to grant the Board of Directors of the Company (the "Board") discretionary authority to amend the Certificate of Incorporation to effect a reverse stock split of Common Stock at a ratio in the range from one-for-two to one-for ten with the exact ratio, if any, to be determined by the Board, but not later than one year after stockholder approval thereof.

For Against Abstain Broker Non-Vote
26,180,980 397,262 252 0
III. Proposal to approve the Company's 2026 Equity Incentive Plan.
For Against Abstain Broker Non-Vote
24,887,762 339,193 4,403 1,347,136
IV. Proposal to approve the Company's 2026 Employee Stock Purchase Plan.
For Against Abstain Broker Non-Vote
24,580,773 648,533 2,052 1,347,136
V. Proposal to elect five director nominees who will serve until the 2027 annual meeting or until their successors are duly elected and qualified.
Name For Against Withheld Broker Non-Vote
Vijay Aggarwal 25,093,904 0 137,454 1,347,136
Thomas W. Burnell 25,095,783 0 135,575 1,347,136
Joseph D. Keegan, Ph.D. 24,422,783 0 808,575 1,347,136
Fortunato Ron Rocca 24,422,706 0 808,652 1,347,136
Stephen J. Sullivan 24,422,713 0 808,645 1,347,136
VI. Proposal to approve a non-binding advisory vote on a resolution approving the compensation of our named executive officers.
For Against Abstain Broker Non-Vote
24,952,970 249,460 28,928 1,347,136
VII. Proposal to ratify the appointment of EisnerAmper, LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2026.
For Against Abstain Broker Non-Vote
26,442,760 134,660 1,074 0
Interpace Biosciences Inc. published this content on August 21, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on August 21, 2026 at 10:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]